EUCTR2012-002249-39-BE进行中（未招募）1 期
Phase 2 Study of Ipilimumab in Children and Adolescents (12<18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- 12 < 18 years of age
- •- Previously Treated or Untreated, Unresectable - Stage III or Stage IV Malignant Melanoma
- •KPS or Lansky Score of = 50
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 40
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Primary Ocular Melanoma
- •- Prior therapy with CTLA-4 or PD-1 antagonist, or PD-L1 or CD137 agonists
- •- Symptomatic brain metastases
- •- History of autoimmune disease
研究者
相似试验
进行中（未招募）
1 期
Phase 2 Study of Ipilimumab in Children and Adolescents (12<18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant MelanomaMalignant MelanomaMedDRA version: 14.1Level: PTClassification code 10025650Term: Malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002249-39-FRBristol-Myers Squibb International Corporation40
进行中（未招募）
1 期
Phase 2 Study of Ipilimumab in Children and Adolescents (12<18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant MelanomaRevised Protocol 01 incorporating Amendment 04Revised EMA PIP P/0093/2014 (dated 07Apr2014)Malignant MelanomaMedDRA version: 17.1Level: PTClassification code 10025650Term: Malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002249-39-ITBristol-Myers Squibb International Corporation14
进行中（未招募）
1 期
Phase 2 Study of Ipilimumab in Children and Adolescents (12<18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant MelanomaEUCTR2012-002249-39-DEBristol-Myers Squibb International Corporation40
进行中（未招募）
1 期
Phase 2 Study of Ipilimumab in Children and Adolescents (12<18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant MelanomaMalignant MelanomaMedDRA version: 17.0Level: PTClassification code 10025650Term: Malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002249-39-DKBristol-Myers Squibb International Corporation40
进行中（未招募）
1 期
Phase 2 Study of Ipilimumab in Children and Adolescents (12<18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant MelanomaMalignant MelanomaMedDRA version: 17.0 Level: PT Classification code 10025650 Term: Malignant melanoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002249-39-GBBristol-Myers Squibb International Corporation14